治理缺口：通过决策架构推动药物研发民主化
The Governance Gap: Democratizing Drug Development Through Decision Architecture
作者：Craig R. Rayner、Nancy E. Martin、Danielle Smith、Eliza Kruger、Carl M.J. Kirkpatrick、Goonaseelan (Colin) Pillai、Katy Moore、Darrell Nix、Cristina Donini、Jakob P. Cramer、Edmundo Muniz、Natalia Muniz、Ernst Bos、Douglas McNair、Shyam Bhaskaran、Mark Sullivan、Dan Hartman
单位：Oktopi Pty Ltd, Melbourne, Victoria and Brisbane, Queensland, Australia.；Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.；Gates Foundation, Seattle, Washington, USA.；Medicines Development for Global Health, Melbourne, Victoria, Australia.；Verida Advisory, Broulee, New South Wales, Australia.；Pharmacometrics Africa NPC, Cape Town, South Africa.；Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.；CP+ Associates GmbH, Basel, Switzerland.
摘要
《临床药理学与治疗学》（ASCPT官方期刊）于2026年9月7日在线发表观点文章，探讨当前药物研发决策体系中的治理缺陷，主张通过优化决策架构促进利益相关方参与，降低研发门槛并提升研发效率。
AI 主编 · 推荐理由推荐理由
文章直指创新药研发周期长、成本高、风险集中的结构性问题，提出以决策架构改革赋能多元化研发主体。适合关注药物研发模式创新、监管科学及行业生态建设的注册、战略与BD负责人阅读，可启发对新药研发支持政策的思考。